← Leaderboards
Mario Lacouture
National Jewish Health
$1,025,459
Attributed
$3,076,377
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $638.6K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,076,377 · 1
By mechanism
U01$3,076,377 · 1
Top collaborators
- Jeffrey A Kern5 shared
- Donald Ym Leung5 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Elena Goleva$2,832,790
- Robert Carl Murphy$18,062,548
- Yosef Refaeli$4,091,114
- Max A Seibold$17,544,388
- Vineela Kadiyala$161,724
Others in their field
Other Emerging Leaders on “Event”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Ted Ross · University Of Georgia$70,992,558
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Olwen Hahn · Brigham And Women'S Hospital$36,805,199
Research focus
EventEndocannabinoidsAdrenal Cortex HormonesAnti-Inflammatory AgentsAnti-Pd-L1AffectAnti-Ctla4Adverse EventAutoinflammatoryBiobankBiologicalBiological MarkersApplications GrantsBloodCancer ImmunotherapyCancer TherapyClinical PhenotypeCutaneousCytokineCytokine ActivationDermatologicDoseEarly IdentificationFilaggrin
Grant awards (5)
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$608,731
U01 · FY2024 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$613,843
U01 · FY2023 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$610,938
U01 · FY2022 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$604,257
U01 · FY2021 · AR
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy$638,608
U01 · FY2020 · AR